Glycemic impact of gabapentin and Nucleo C.M.P in metformin-controlled diabetic patients: A case report
- PMID: 39055669
- PMCID: PMC11271094
- DOI: 10.1177/2050313X241265072
Glycemic impact of gabapentin and Nucleo C.M.P in metformin-controlled diabetic patients: A case report
Abstract
This study examines the contraindications of gabapentin and Nucleo C.M.P Forte in metformin-controlled diabetic patients, focusing on their potential to induce hyperglycemia. A case report of a 65-year-old woman with type II diabetes is presented, demonstrating elevated blood glucose levels following the initiation of gabapentin and Nucleo C.M.P Forte. The literature review highlights limited data on gabapentin-induced hyperglycemia, with additional consideration of the potential effects of Nucleo C.M.P Forte. The study suggests modifying insulin therapy in diabetic patients taking gabapentin and calls for further research on this interaction.
Keywords: Metformin; diabetes mellitus; diabetic neuropathy; gabapentin; intervertebral disk displacement.
© The Author(s) 2024.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
A probable case of gabapentin-related reversible hearing loss in a patient with acute renal failure.Clin Ther. 2008 Sep;30(9):1681-4. doi: 10.1016/j.clinthera.2008.09.004. Clin Ther. 2008. PMID: 18840374
-
Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.Diabetes Res Clin Pract. 2002 Jan;55(1):65-85. doi: 10.1016/s0168-8227(01)00365-5. Diabetes Res Clin Pract. 2002. PMID: 11755481
-
Metformin as an adjunct to insulin for glycemic control in patients with type 2 diabetes after CABG surgery: a randomized double blind clinical trial.Pak J Biol Sci. 2011 Dec 1;14(23):1047-54. doi: 10.3923/pjbs.2011.1047.1054. Pak J Biol Sci. 2011. PMID: 22590838 Clinical Trial.
-
An overview of metformin in the treatment of type 2 diabetes mellitus.Am J Med. 1997 Jan;102(1):99-110. doi: 10.1016/s0002-9343(96)00353-1. Am J Med. 1997. PMID: 9209206 Review.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
References
-
- Goa K, Sorkin E. Gabapentin. Drugs 1993; 46: 409–427. - PubMed
-
- McLean M, Gidal B. Gabapentin dosing in the treatment of epilepsy. Clin Ther 2003; 25: 1382–1406. - PubMed
-
- Martynyuk L, Makarchuk N, Shved M, et al.. The clinical efficacy of nucleo CMP forte usage in the combined treatment of diabetic peripheral neuropathy. Endocr Abstr 2017; 49: P674.
-
- Alfaris AA, Radha ZH, Hamza BS. Efficacy of nucleo CMP forte in traumatic brain injury in pediatrics: a randomized controlled trial. Pain Manag 2023; 9: 123–129.
-
- Povedano M, Martinez Y, Tejado A, et al.. Observational pilot study of patients with carpal tunnel syndrome treated with Nucleo CMP Forte™. Pain Manag 2019; 9: 123–129. - PubMed
Publication types
LinkOut - more resources
Full Text Sources